Canadian Urological Association guideline: Diagnosis, management, and surveillance of neurogenic lower urinary tract dysfunction - Full text

Alex Kavanagh; Richard Baverstock; Lysanne Campeau; Kevin Carlson; Ashley Cox; Duane Hickling; Genviève Nadeau; Lynn Stothers; Blayne Welk

doi:10.5489/cuaj.5912

Canadian Urological Association guideline: Diagnosis, management, and surveillance of neurogenic lower urinary tract dysfunction - Full text

Alex Kavanagh, Richard Baverstock, Lysanne Campeau, Kevin Carlson, Ashley Cox, Duane Hickling, Genviève Nadeau, Lynn Stothers, Blayne Welk

Medicine

Producción científica: Contribución a una revista › Artículo de revisión › revisión exhaustiva

45 Citas (Scopus)

Idioma original	English
Páginas (desde-hasta)	E157-E176
Publicación	Journal of the Canadian Urological Association
Volumen	13
N.º	6
DOI	https://doi.org/10.5489/cuaj.5912
Estado	Published - 2019

Nota bibliográfica

Funding Information:
Competing interests: Dr. Kavanagh has been an advisory board member for Paladin Labs, and has received a research grant from Astellas. Dr. Baverstock has been a speaker for Allergan, Astellas, BSCI, and Pfizer; and has participated in clinical trials supported by Astellas and Pfizer. Dr. Campeau has been an advisory board and speaker bureau member for Asetllas and Pfizer; has received grants/honoraria from Allergan, Astellas, and Pfizer; and has participated in clinical trials supported by Pfizer. Dr. Cox has been an advisory board member for Pfizer; a speakers bureau member for Astellas and Pfizer; has received grants/honoraria from Astellas and Pfizer; and has participated in clinical trials supported by Aquinox. Dr. Hickling has been an advisory board member for Pfizer; a speakers bureau member for Allergan, Astellas and Pfizer; has received grants/honoraria from Allergan, Astellas and Pfizer; and has participated in clinical trials supported by Astellas. Dr. Nadeau has been an advisory board member for Allergan, AMS, Astellas, Boston Scientific, Ferring, and Pfizer; a speakers bureau member for, Allergan, Astellas, Ferring Laborie, and Pfizer; and and has participated in clinical trials supported by Astellas. The remaining authors report no competing personal or financial interests related to this work.

ASJC Scopus Subject Areas

Oncology
Urology

PubMed: MeSH publication types

Journal Article

Acceder al documento

10.5489/cuaj.5912

Otros archivos y enlaces

Citar esto

Canadian Urological Association guideline: Diagnosis, management, and surveillance of neurogenic lower urinary tract dysfunction - Full text. / Kavanagh, Alex; Baverstock, Richard; Campeau, Lysanne et al.
En: Journal of the Canadian Urological Association, Vol. 13, N.º 6, 2019, p. E157-E176.

Producción científica: Contribución a una revista › Artículo de revisión › revisión exhaustiva

@article{6dd28ce8466a475c8be623e273b9aa95,

title = "Canadian Urological Association guideline: Diagnosis, management, and surveillance of neurogenic lower urinary tract dysfunction - Full text",

author = "Alex Kavanagh and Richard Baverstock and Lysanne Campeau and Kevin Carlson and Ashley Cox and Duane Hickling and Genvi{\`e}ve Nadeau and Lynn Stothers and Blayne Welk",

note = "Funding Information: Competing interests: Dr. Kavanagh has been an advisory board member for Paladin Labs, and has received a research grant from Astellas. Dr. Baverstock has been a speaker for Allergan, Astellas, BSCI, and Pfizer; and has participated in clinical trials supported by Astellas and Pfizer. Dr. Campeau has been an advisory board and speaker bureau member for Asetllas and Pfizer; has received grants/honoraria from Allergan, Astellas, and Pfizer; and has participated in clinical trials supported by Pfizer. Dr. Cox has been an advisory board member for Pfizer; a speakers bureau member for Astellas and Pfizer; has received grants/honoraria from Astellas and Pfizer; and has participated in clinical trials supported by Aquinox. Dr. Hickling has been an advisory board member for Pfizer; a speakers bureau member for Allergan, Astellas and Pfizer; has received grants/honoraria from Allergan, Astellas and Pfizer; and has participated in clinical trials supported by Astellas. Dr. Nadeau has been an advisory board member for Allergan, AMS, Astellas, Boston Scientific, Ferring, and Pfizer; a speakers bureau member for, Allergan, Astellas, Ferring Laborie, and Pfizer; and and has participated in clinical trials supported by Astellas. The remaining authors report no competing personal or financial interests related to this work.",

year = "2019",

doi = "10.5489/cuaj.5912",

language = "English",

volume = "13",

pages = "E157--E176",

journal = "Journal of the Canadian Urological Association",

issn = "1911-6470",

publisher = "Canadian Medical Association",

number = "6",

}

TY - JOUR

T1 - Canadian Urological Association guideline

T2 - Diagnosis, management, and surveillance of neurogenic lower urinary tract dysfunction - Full text

AU - Kavanagh, Alex

AU - Baverstock, Richard

AU - Campeau, Lysanne

AU - Carlson, Kevin

AU - Cox, Ashley

AU - Hickling, Duane

AU - Nadeau, Genviève

AU - Stothers, Lynn

AU - Welk, Blayne

N1 - Funding Information: Competing interests: Dr. Kavanagh has been an advisory board member for Paladin Labs, and has received a research grant from Astellas. Dr. Baverstock has been a speaker for Allergan, Astellas, BSCI, and Pfizer; and has participated in clinical trials supported by Astellas and Pfizer. Dr. Campeau has been an advisory board and speaker bureau member for Asetllas and Pfizer; has received grants/honoraria from Allergan, Astellas, and Pfizer; and has participated in clinical trials supported by Pfizer. Dr. Cox has been an advisory board member for Pfizer; a speakers bureau member for Astellas and Pfizer; has received grants/honoraria from Astellas and Pfizer; and has participated in clinical trials supported by Aquinox. Dr. Hickling has been an advisory board member for Pfizer; a speakers bureau member for Allergan, Astellas and Pfizer; has received grants/honoraria from Allergan, Astellas and Pfizer; and has participated in clinical trials supported by Astellas. Dr. Nadeau has been an advisory board member for Allergan, AMS, Astellas, Boston Scientific, Ferring, and Pfizer; a speakers bureau member for, Allergan, Astellas, Ferring Laborie, and Pfizer; and and has participated in clinical trials supported by Astellas. The remaining authors report no competing personal or financial interests related to this work.

PY - 2019

Y1 - 2019

UR - http://www.scopus.com/inward/record.url?scp=85070925389&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070925389&partnerID=8YFLogxK

U2 - 10.5489/cuaj.5912

DO - 10.5489/cuaj.5912

M3 - Review article

C2 - 30763235

AN - SCOPUS:85070925389

SN - 1911-6470

VL - 13

SP - E157-E176

JO - Journal of the Canadian Urological Association

JF - Journal of the Canadian Urological Association

IS - 6

ER -